Athira Pharma
ATHA
Market cap $22.3M

0.5760 USD

+0.0280

5.11%

At close Dec 20, 4:00 PM EST

After hours

0.5794

+0.0034

0.59%

1 day

5.11%

5 days

-0.69%

1 month

-10.32%

3 months

33.86%

6 months

-74.85%

Year to date

-80.07%

1 year

-72.57%

5 years

-96.63%

10 years

-96.63%

About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Employees: 67

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

13% more call options, than puts

Call options by funds: $52K | Put options by funds: $46K

11% less funds holding

Funds holding: 65 [Q2] → 58 (-7) [Q3]

16.0% less ownership

Funds ownership: 57.96% [Q2] → 41.96% (-16.0%) [Q3]

24% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 17

41% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 17

88% less capital invested

Capital invested by funds: $58.9M [Q2] → $7.19M (-$51.7M) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ATHA.

See Analyst Rankings

Financial journalist opinion

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association's 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada.

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Zacks Investment Research

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23)

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Zacks Investment Research

Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?

Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?

Zacks Investment Research

Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?

Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?

See News Rankings

Charts implemented using Lightweight Charts™